drugset / Trial / NCT06635798

A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

NCT06635798

Phase 3 Recruiting 582 enrolled Genrix (Shanghai) Biopharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The goal of this clinical trial is to compare the efficacy and safety of GR2001 injection with Human Tetanus Immunoglobulin(HTIG) in tetanus prophylaxis. Patients will receive either GR2001 injection or HTIG on study D0.

Timeline

Start
2024-09-03
Primary completion
2024-12-04
Completion
2025-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject GR2001 Unknown Intramuscular
Comparator Human Tetanus Immunoglobulin Protein / enzyme biologic Intramuscular

Indications